03:27 AM EDT, 03/27/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said late Thursday the US Food and Drug Administration has approved its experimental drug, Awiqli, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

The company said the drug is the first once-weekly basal insulin option, offering an alternative to daily dosing.

The approval is based on a phase 3 program involving about 2,680 adults with uncontrolled type 2 diabetes across four randomized studies, the drugmaker said.

Novo Nordisk ( NVO ) said it plans to launch the drug in the US in H2 2026 using its FlexTouch delivery device, adding that the therapy has also been approved in the EU and several other markets.